HC Wainwright Raises Earnings Estimates for BridgeBio Pharma

Key Points

• HC Wainwright slightly raised Q1 2026 EPS to ($0.61), kept a "Buy" rating and a $100 price target, and projects FY2027 profitability (~$1.83 EPS) with multiple profitable quarters in 2027 while trimming FY2026 estimates to about ($1.76), signaling near‑term risk but stronger medium‑term outlook.
• BridgeBio reported Q4 EPS of ($1.00) (missing estimates) while revenue of $154.18M beat expectations and rose ~2521% YoY, and the stock jumped about 13% amid broad price‑target upgrades from firms including Wells Fargo, JPMorgan and Truist and a consensus target near $83.35.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Analysts at HC Wainwright raised their Q1 2026 earnings estimates for BridgeBio Pharma in a report released on Monday, March 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.61) per share for the quarter, up from their prior forecast of ($0.62). HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma's Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.76) EPS, Q1 2027 earnings at $0.03 EPS, Q2 2027 earnings at $0.42 EPS, Q3 2027 earnings at $0.57 EPS and Q4 2027 earnings at $0.80 EPS.

A number of other brokerages have also issued reports on BBIO. Wells Fargo & Company lifted their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an "overweight" rating in a research note on Friday, February 13th. Barclays reaffirmed an "overweight" rating on shares of BridgeBio Pharma in a report on Tuesday. William Blair started coverage on shares of BridgeBio Pharma in a research report on Tuesday. They set an "outperform" rating on the stock. Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the company an "outperform" rating in a research note on Thursday, February 12th. Finally, Truist Financial raised their target price on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $83.35.

BridgeBio Pharma Trading Up 13.2%

BBIO stock opened at $74.32 on Wednesday. The business's 50-day moving average is $73.42 and its 200 day moving average is $65.74. BridgeBio Pharma has a 12-month low of $28.33 and a 12-month high of $84.94. The stock has a market cap of $14.41 billion, a price-to-earnings ratio of -19.66 and a beta of 1.13.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analysts' expectations of $150.71 million. The business's quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.40) earnings per share.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently made changes to their positions in the stock. Invesco Ltd. increased its holdings in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company's stock valued at $369,547,000 after purchasing an additional 902,648 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of BridgeBio Pharma by 8.9% during the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company's stock worth $4,105,000 after buying an additional 4,448 shares during the period. XTX Topco Ltd grew its stake in shares of BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company's stock valued at $1,007,000 after buying an additional 8,150 shares in the last quarter. VARCOV Co. acquired a new stake in shares of BridgeBio Pharma in the fourth quarter valued at $340,000. Finally, Voloridge Investment Management LLC increased its stake in BridgeBio Pharma by 377.4% during the fourth quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company's stock worth $48,868,000 after purchasing an additional 505,051 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total value of $2,877,600.00. Following the completion of the sale, the chief executive officer owned 695,686 shares of the company's stock, valued at $50,047,650.84. This represents a 5.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Maricel Apuli sold 510 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10. Following the sale, the chief accounting officer owned 123,945 shares of the company's stock, valued at $9,210,352.95. This represents a 0.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 227,095 shares of company stock worth $16,099,240 over the last ninety days. 18.20% of the stock is currently owned by insiders.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright keeps a "Buy" rating and a $100 price target while projecting strong FY2027 profitability (FY2027 EPS ~ $1.83) and multiple profitable quarters in 2027 — this signals analysts expect BridgeBio's pipeline and revenue to produce material upside over the next 12–18 months. Read More.
• Positive Sentiment: JPMorgan raised its price target to $94 and maintained an "Overweight" view, providing another institutional upwardly revised target that supports today's momentum. Read More.
• Positive Sentiment: William Blair initiated coverage with an "Outperform" rating, adding distribution of a positive analyst view that can attract new institutional buyers. Read More.
• Positive Sentiment: Press coverage is amplifying the upgrades and pipeline narrative (articles note price‑target upgrades and renewed growth buzz around BridgeBio’s rare‑disease programs), which can fuel retail and momentum flows. Read More. Read More.
• Neutral Sentiment: BridgeBio appeared on an investor watchlist roundup (InsiderMonkey) — increases visibility but not necessarily a direct catalyst. Read More.
• Neutral Sentiment: Reported short‑interest data in the filings shows zero/erroneous values (likely a data anomaly), so short‑squeeze dynamics do not appear to be a meaningful driver based on the available figures. Read More.
• Negative Sentiment: HC Wainwright trimmed several near‑term 2026 estimates and cut FY2026 EPS (now ~ -$1.76), reflecting expected weaker near‑term profitability — a reminder of execution and timing risk for the company's programs and revenues. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.